https://orcid.org/0000-0001-8271-2033
References
- Staples JE, Breiman RF, Powers AM. Chikungunya fever: an epidemiological review of a re‐emerging infectious disease. Clin Infect Dis. 2009;49(6):942–2. doi: 10.1086/605496
- Chikungunya. Cdc.gov. Accessed November 12, 2023. Available from: https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/chikungunya
- Chikungunya. Who.int. Accessed November 12, 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/chikungunya
- Ganesan V, Duan B, Reid S. Chikungunya virus: Pathophysiology, mechanism, and modeling. Viruses. 2017;9(12):368. doi: 10.3390/v9120368
- Cherian N, Bettis A, Deol A, et al. Strategic considerations on developing a CHIKV vaccine and ensuring equitable access for countries in need. NPJ Vaccin. 2023;8(1). doi: 10.1038/s41541-023-00722-x
- Singh SK, Unni SK. Chikungunya virus: host pathogen interaction: Chikungunya virus. Rev Med Virol. 2011;21(2):78–88. doi: 10.1002/rmv.681
- Chikungunya vaccines: An update in 2023. Asian Pac J Allergy Immunol. 2023. doi: 10.12932/ap-271222-1520
- FDA approves first vaccine to prevent disease caused by Chikungunya virus. U.S. Food and Drug Administration. Published November 9, 2023. Accessed November 12, 2023. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-prevent-disease-caused-chikungunya-virus
- Schneider M, Narciso-Abraham M, Hadl S, et al. Safety and immunogenicity of a single- shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2023;401(10394):2138–2147. doi: 10.1016/s0140-6736(23)00641-4